September 13, 2008; 9:00 - 10:30 N. El Saghir Introduction T. Cufer The 2007 St. Gallen guidelines and/or adjuvant on-line C. Sotiriou Treatment tailoring based on molecular characterization I. Smith Treatment decision-making in advanced disease September 13, 2008; 9:00 - 10:30 J. Mackay What new technology and what for ? L. Gianni Is there an impact on the treatment of breast cancer? D. Kerr Is there an impact on the treatment of colorectal cancer ? September 13, 2008; 10:45 - 12:15 I. Tannock The changing face of hormonal therapy M.R. Smith Diabetes and cardiovascular disease in prostate cancer survivors C.N. Sternberg Systemic chemotherapy and new experimental approaches September 13, 2008; 10:45 - 12:15 A. Psyrri Viruses in head and neck cancers: prevention and therapy J. Giralt Strengths and weaknesses in multidisciplinary treatment of locally advanced head and neck cancer L. Licitra Recurrent and metastatic head and neck cancer: new options September 13, 2008; 12:45 - 13:35 R. Bernards Using the Genome to Improve the Diagnosis and Treatment of Cancer September 13, 2008; 14:00 - 15:30 P.E. Postmus Screening and early diagnosis W. Weder Changing algorithm in staging G. Giaccone New opportunities in systemic therapy September 13, 2008; 14:00 - 15:30 M. Dicato Erythropoietic stimulating agents. Where do we stand? P. Niscola Mucositis in the treatment of hematologic malignancies J. Tabernero Handling side effects of targeted agents September 13, 2008; 15:45 - 17:15 D. Cunningham Perioperative management of gastroesophageal cancer A. Cervantes Perioperative management of rectal cancer V. Heinemann Perioperative management of pancreatic cancer September 13, 2008; 15:45 - 17:15 A. Decensi Inflammation and cancer prevention L. Sanda Eliminating tobacco-induced cancers: a worldwide challange H.-J. Senn Chemoprevention of breast and prostate cancer: Where do we stand ? September 14, 2008; 9:00 - 10:30 H. Mellstedt Overcoming immunosuppressor mechanismus J. Copier Anti cancer vaccines: emerging clinical data H. Zwierzina Combining immunotherapy with classical anti-cancer therapy September 14, 2008; 9:15 - 10:15 E. Van Cutsem Introduction C. Punt Pro speaker A. De Gramont Contra speaker E. Van Cutsem Conclusion September 14, 2008; 10:45 - 12:15 J. Bladé Prognostic factors in the management of myeloma M. Dimopoulos The role of novel drugs in myeloma P. Moreau The status of transplantation in myeloma September 14, 2008; 10:45 - 12:45 N. Pavlidis/R.A. Stahel Introduction and questionnaire F. Roila Thrombosis 1st Case: VTE and Prophylaxis 57-year-old patient... R. Labianca Discussant - ESMO CR: Thrombosis M. Castiglione Cancer and pregnancy (cancer during pregnancy and pregnancy after cancer) 1st case:... G. Pentheroudakis Discussant - ESMO CR: Cancer and pregnancy J. Oliveira Gastric cancer 1st case D. Cunningham Discussant - ESMO CR: Gastric cancer --> September 14, 2008; 12:30 - 13:20 L. Norton Evolution, Stem Cells, and Metastases: Changing Theories of Neoplasia and their Practical Implications September 14, 2008; 13:30 - 14:30 F. Andre Introduction S. Michiels Pro speaker A. Gennari Contra speaker F. Andre Conclusion September 14, 2008; 13:45 - 15:15 K. Herholz Imaging of glioma B.G. Baumert Role of radiotherapy in low grade glioma September 14, 2008; 15:30 - 17:00 H. Wildiers Breast cancer D. Papamichael Colon cancer C. Gridelli Lung cancer September 14, 2008; 16:30 - 17:30 R. Labianca Introduction H.-M.M.B. Otten Pro speaker A. Kakkar Contra speaker R. Labianca Conclusion September 15, 2008; 7:45 - 8:45 A. Gennari Breast Cancer, Advanced M.C. Merlano Head and neck cancer E. Calvo Aller Developmental therapeutics S. Van Belle Palliative and supportive care H.-J. Schmoll Gastrointestinal tumors September 15, 2008; 9:15 - 10:15 M. Untch Introduction J. Crown Pro speaker I. Smith Contra speaker M. Untch Conclusion September 15, 2008; 12:30 - 13:20 W. Kaelin Treatment of Kidney Cancer: The VHL Protein as a Rosetta Stone September 15, 2008; 15:15 - 17:30 --> C. Manegold BO17704 (Avail): A Phase III Randomised Study of First-Line Bevacizumab... J. Soria Discussant LBA1 T. Mok PHASE III, Randomised, Open-Label, First-Line Study Of Gefitinib (G) Vs Carboplatin/Paclitaxel (C/P) F. Cappuzzo Discussant LBA2 R. Midgley Victor: A Phase III Placebo-Controlled Trial of Rofecoxib In Colorectal Cancer Patients Following Surgical Resection E. Van Cutsem Discussant LBA3 B. Monk A Randomized Phase III Study of Trabectedin with Pegylated Liposomal Doxorubicin (PLD)... C. Sessa Discussant LBA4 S. Lee A Randomised Trial of Procarbazine, CCNU and Vincristine (PCV) vs Temozolomide --> September 16, 2008; 7:45 - 8:45 A. Gennari Breast cancer, early M. Ignatiadis Basic science and bench to bedside E. Felip Chest tumors F. Calabrò Genitourinary tumors E. Pujade-Lauraine Gynecological cancer H. Schouten Hematological malignancies September 16, 2008; 9:00 - 10:30 P. Vasey Ovarian cancer: front-line standard treatment in 2008 N. Reed Endometrial cancer: adjuvant treatment of endometrial cancer: radiotherapy, chemotherapy or both? A. Poveda Cervical cancer: treatment update September 16, 2008; 9:15 - 10:15 A. Gronchi Introduction R. Issels Pro speaker M. Robinson Contra speaker A. Gronchi Conclusion September 16, 2008; 9:00 - 10:30 G. Rustin Germ cell tumors I. Judson Soft tissue sarcoma